Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Brentuximab Vedotin in Combination With Pembrolizumab in Participants With Metastatic Solid Malignancies

NCT04609566 is registered in ClinicalTrials.gov with Seagen, a wholly owned subsidiary of Pfizer as lead sponsor.

NCT NCT04609566
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04609566 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Brentuximab Vedotin in Combination With Pembrolizumab in Participants With Metastatic Solid Malignancies
Lead sponsor
Seagen, a wholly owned subsidiary of Pfizer
Phase
Phase 2
Overall status
Completed
Start date
January 26, 2021
Completion date
February 3, 2026
Enrollment
161 (actual)
Sites
90

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma, non-small cell lung cancer, squamous cell carcinoma of the head and neck